Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adherex gains rights to eniluracil
As a result, Adherex will assume full direction over the product's future development pursuant to the terms of the license, including the ability to partner and sub-license the
As a result, Adherex will assume full direction over the product's future development pursuant to the terms of the license, including the ability to partner and sub-license the
GenVec's technology is used for the production of recombinant adenovirus vaccine vectors. GenVec has been collaborating with the Naval Medical Research Center for the past four years to
Exforge combines in one tablet the power of the two most commonly prescribed branded hypertension medicines, Diovan and Norvasc. Exforge is indicated for the treatment of hypertension in
The findings to date indicate that PRX302 is well tolerated and shows encouraging signs of therapeutic activity following a single intra-prostatic injection. This trial is intended to examine
The phase IIa trial examined two doses of AZ-004, 5 and 10 mg, and placebo. The primary aim of the trial was to assess the safety and efficacy
However, the product candidate 1207 did achieve the primary endpoint of safety and tolerability. In addition to safety data, the study measured sensory perceptions of touch and warmth
Sutent is an oral therapy belonging to a new class of drugs that attack cancer by inhibiting tumor growth and starving the tumor of blood, thereby reducing its
Saforis is an investigational therapy for the treatment and prevention of oral mucositis in patients receiving mucotoxic cancer therapy. The phase III trial of Saforis was conducted in
Barr anticipates receiving final approval following the expiration of Roche's patent in December 2007, or in June 2008 if Roche seeks and is granted pediatric exclusivity. Kytril is
The primary objective of the head-to-head trial is to compare the immune responses to two of the most common cancer causing strains of the human papillomavirus (HPV) in